A professional file card for Novartis’ Exelon makes unsubstantiated superiority claims, overstates the drug’s efficacy, includes misleading risk presentations and recommends or suggests an unapproved use, says the FDA. It wants Novartis to submit a plan for circulating corrective materials.
From the October 01, 2007 Issue of MM+M - Medical Marketing and Media
